OpinionAnalysis

Questioning Lipid Nanoparticles

Save
Questioning Lipid Nanoparticles
Holiday.Photo.Top/Shutterstock
David Gortler
Updated:
0:00
News Analysis
Despite over 13.5 billion COVID-19 doses administered worldwide, there remains a lot of fundamental information lacking. Since there isn’t a good article which 1) scientifically, 2) clinically and 3) regulatorily address Lipid Nanoparticles (LNPs) and the FDA’s role in assuring and regulating novel technologies and ingredients, I am writing one.
David Gortler
David Gortler
Author
Dr. David Gortler, a 2023 Brownstone Fellow, is a pharmacologist, pharmacist, research scientist, and a former member of the FDA Senior Executive Leadership Team who served as senior advisor to the FDA Commissioner on matters of: FDA regulatory affairs, drug safety and FDA science policy. He is a former Yale University and Georgetown University didactic professor of pharmacology and biotechnology, with over a decade of academic pedagogy and bench research, as part of his nearly two decades of experience in drug development. He also serves as a scholar at the Ethics and Public Policy Center.
twitter
Related Topics